HBIO - Harvard Bioscience Inc Stock Price, Fair Value and News

3.39USD-0.05 (-1.45%)Delayed

Market Summary

USD3.39-0.05

Delayed

-1.45%

HBIO Stock Price

View Fullscreen

HBIO RSI Chart

HBIO Valuation

Market Cap

147.2M

Price/Earnings (Trailing)

-16.86

Price/Sales (Trailing)

1.38

EV/EBITDA

-52.1

Price/Free Cashflow

12.9

HBIO Price/Sales (Trailing)

HBIO Profitability

EBT Margin

-7.72%

Return on Equity

-12.69%

Return on Assets

-6.56%

Free Cashflow Yield

7.75%

HBIO Fundamentals

HBIO Revenue

Revenue (TTM)

106.8M

Rev. Growth (Yr)

-18.23%

Rev. Growth (Qtr)

-12.93%

HBIO Earnings

Earnings (TTM)

-8.7M

Earnings Growth (Yr)

-854.66%

Earnings Growth (Qtr)

-158.2%

Breaking Down HBIO Revenue

Last 7 days

-4.0%

Last 30 days

-17.1%

Last 90 days

-25%

Trailing 12 Months

-39.4%

How does HBIO drawdown profile look like?

HBIO Financial Health

Current Ratio

1.88

Debt/Equity

0.46

Debt/Cashflow

0.43

HBIO Investor Care

Shares Dilution (1Y)

2.94%

Diluted EPS (TTM)

-0.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	106.8M	0	0	0
2023	114.5M	114.1M	112.5M	112.3M
2022	120.7M	120.7M	118.0M	113.3M
2021	105.3M	111.2M	116.8M	118.9M
2020	111.7M	105.5M	102.1M	102.1M
2019	122.2M	120.3M	119.1M	116.2M
2018	86.1M	98.6M	108.6M	120.8M
2017	95.6M	88.5M	82.2M	77.4M
2016	109.9M	107.2M	106.5M	104.5M
2015	108.5M	110.4M	110.7M	108.7M
2014	105.0M	105.8M	106.2M	108.7M
2013	108.9M	106.5M	105.6M	105.2M
2012	110.9M	112.2M	112.0M	111.2M
2011	108.2M	109.4M	109.4M	108.9M
2010	0	93.2M	100.7M	108.2M
2009	0	0	0	85.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Harvard Bioscience Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 06, 2024	cote jennifer	sold (taxes)	-40,771	4.11	-9,920	chief financial officer
Mar 05, 2024	green james w	acquired	-	-	429,594	chief executive officer
Mar 05, 2024	cote jennifer	acquired	-	-	71,600	chief financial officer
Dec 31, 2023	green james w	sold (taxes)	-442,926	5.35	-82,790	chief executive officer
Dec 29, 2023	green james w	sold (taxes)	-686,897	5.35	-128,392	chief executive officer
Dec 29, 2023	cote jennifer	sold (taxes)	-31,618	5.35	-5,910	chief financial officer
Aug 17, 2023	green james w	bought	109,500	4.38	25,000	chief executive officer
Jun 11, 2023	green james w	sold (taxes)	-264,117	5.46	-48,373	chief executive officer
May 22, 2023	edrick alan i	acquired	-	-	25,554	-
May 22, 2023	eade katherine a.	acquired	-	-	25,554	-

Which funds bought or sold HBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	82,837	82,837	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-18,419	17,282	-%
May 16, 2024	Brown Shipley& Co Ltd	reduced	-0.98	-5,414	20,175	0.01%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	reduced	-1.3	-1,586,940	5,699,870	0.11%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-0.85	-46,163	169,303	-%
May 15, 2024	Royal Bank of Canada	reduced	-89.2	-65,000	6,000	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	80,501	80,501	-%
May 15, 2024	Granahan Investment Management, LLC	added	1.1	-1,960,340	7,902,300	0.28%
May 15, 2024	Voya Investment Management LLC	reduced	-15.5	-30,333	61,505	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-7.01	-279,160	782,280	0.02%

Are Funds Buying or Selling HBIO?

Are funds buying HBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HBIO

No. of Funds

Unveiling Harvard Bioscience Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 19, 2024	leviticus partners lp	5.32%	2,308,622	SC 13G
Feb 14, 2024	harvey partners, llc	6.0%	2,557,500	SC 13G/A
Feb 14, 2024	punch & associates investment management, inc.	6.80%	2,918,034	SC 13G/A
Feb 14, 2024	b. riley asset management, llc	6.9%	2,939,278	SC 13G/A
Jan 26, 2024	blackrock inc.	6.8%	2,913,814	SC 13G
Jan 22, 2024	leviticus partners lp	4.94%	2,106,670	SC 13G/A
Aug 28, 2023	leviticus partners lp	5.06%	2,158,794	SC 13G
Feb 16, 2023	b. riley asset management, llc	7.8%	3,264,796	SC 13G/A
Feb 15, 2023	b. riley asset management, llc	7.84%	3,264,796	SC 13G
Feb 14, 2023	harvey partners, llc	7.0%	2,911,500	SC 13G

Recent SEC filings of Harvard Bioscience Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 03, 2024	8-K	Current Report
Apr 03, 2024	ARS	ARS
Apr 03, 2024	DEF 14A	DEF 14A
Apr 03, 2024	DEFA14A	DEFA14A
Mar 26, 2024	8-K	Current Report
Mar 19, 2024	SC 13G	Major Ownership Report
Mar 07, 2024	10-K	Annual Report

Peers (Alternatives to Harvard Bioscience Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.1M	3.7M	-71.13%	32.26%	-0.09	0.29	5.77%	8.23%

Harvard Bioscience Inc News

Latest updates

Harvard Bioscience Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-12.9%	24,512	28,153	25,363	28,759	29,975	28,427	26,922	29,208	28,778	33,055	29,663	29,197	26,989	30,984	24,037	23,308	23,771	30,972	27,418	29,584	28,202
Gross Profit	-9.5%	14,772	16,325	14,727	16,673	18,346	15,833	12,172	16,637	16,177	19,560	16,308	16,353	15,431	17,708	13,495	13,856	12,982	17,234	14,979	15,955	16,154
Operating Expenses	6.3%	17,051	16,043	15,660	15,877	16,597	16,290	15,934	12,639	22,889	17,861	15,760	16,295	15,670	14,952	13,313	13,300	16,255	15,601	16,344	15,727	16,274
S&GA Expenses	-5.1%	5,904	6,220	5,732	6,178	5,978	5,948	5,819	6,587	6,687	7,343	6,183	5,730	5,386	5,470	4,588	4,279	5,579	5,894	5,294	5,770	6,306
R&D Expenses	-8.4%	2,885	3,150	2,760	2,957	2,897	2,849	2,763	3,497	3,220	2,951	2,660	2,701	2,487	2,349	1,949	1,897	2,490	2,645	2,564	2,771	2,735
EBITDA Margin	-228.8%	-0.03*	0.02*	0.03*	-0.01*	0.03*	-0.05*	-0.03*	0.01*	-0.03*	0.03*	0.02*	0.02*	-	-	-	-	-	-	-	-	-
Interest Expenses	-2.7%	768	789	858	976	1,172	785	684	462	383	741	2.00	376	458	1,086	1,246	1,312	1,237	1,318	1,348	1,376	1,406
Income Taxes	-71.4%	200	699	677	-1,100	600	737	-1,285	986	-100	167	200	-200	-15.00	43.00	-317	713	55.00	-452	-100	-885	576
Earnings Before Taxes	-306.5%	-4,484	-1,103	-562	-2,098	1,207	-892	-4,690	3,421	-7,018	1,131	45.00	-632	-684	-548	-1,415	-868	-4,461	98.00	-2,674	-1,132	-1,794
EBT Margin	-239.2%	-0.08*	-0.02*	-0.02*	-0.06*	-0.01*	-0.08*	-0.06*	-0.02*	-0.05*	0.00*	-0.02*	-0.03*	-	-	-	-	-	-	-	-	-
Net Income	-158.2%	-4,694	-1,818	-1,239	-980	622	-1,666	-3,405	2,435	-6,880	961	-170	-410	-669	-615	-1,098	-1,581	-4,516	550	-2,620	-247	-2,370
Net Income Margin	-168.7%	-0.08*	-0.03*	-0.03*	-0.05*	-0.02*	-0.08*	-0.06*	-0.03*	-0.05*	0.00*	-0.02*	-0.03*	-	-	-	-	-	-	-	-	-
Free Cashflow	-78.2%	758	3,473	4,144	3,035	1,588	2,444	207	-632	-2,457	-241	-1,140	562	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.1%	133	137	140	143	146	145	147	155	158	162	154	154	151	156	150	151	156	165	163	166	171
Current Assets	-1.8%	48.00	49.00	50.00	53.00	52.00	51.00	52.00	56.00	59.00	62.00	56.00	54.00	49.00	52.00	44.00	44.00	48.00	54.00	52.00	52.00	54.00
Cash Equivalents	-0.7%	4.00	4.00	5.00	4.00	4.00	5.00	5.00	4.00	5.00	8.00	6.00	6.00	6.00	8.00	3.00	3.00	6.00	8.00	7.00	5.00	5.00
Inventory	-2.3%	24.00	25.00	26.00	26.00	27.00	26.00	26.00	29.00	29.00	28.00	26.00	25.00	23.00	22.00	23.00	23.00	23.00	22.00	24.00	25.00	27.00
Net PPE	12.8%	4.00	4.00	3.00	3.00	3.00	3.00	4.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	6.00
Goodwill	-0.6%	57.00	57.00	56.00	57.00	57.00	56.00	55.00	56.00	57.00	58.00	58.00	58.00	58.00	59.00	58.00	57.00	57.00	57.00	57.00	57.00	57.00
Liabilities	0.1%	64.00	64.00	65.00	68.00	71.00	73.00	75.00	78.00	82.00	79.00	77.00	75.00	74.00	80.00	72.00	75.00	80.00	83.00	86.00	86.00	91.00
Current Liabilities	-3.3%	26.00	27.00	24.00	23.00	23.00	23.00	21.00	23.00	27.00	25.00	24.00	23.00	21.00	21.00	21.00	23.00	23.00	25.00	22.00	21.00	24.00
Long Term Debt	3.9%	32.00	31.00	35.00	38.00	41.00	43.00	47.00	46.00	46.00	45.00	43.00	41.00	42.00	46.00	41.00	41.00	46.00	47.00	52.00	52.00	54.00
LT Debt, Non Current	-100.0%	-	31.00	35.00	38.00	41.00	43.00	47.00	46.00	46.00	45.00	43.00	41.00	42.00	46.00	41.00	41.00	46.00	47.00	52.00	52.00	54.00
Shareholder's Equity	-5.8%	69.00	73.00	74.00	75.00	74.00	72.00	72.00	78.00	76.00	83.00	77.00	79.00	77.00	77.00	77.00	76.00	76.00	82.00	77.00	80.00	80.00
Retained Earnings	-3.2%	-150	-145	-143	-142	-141	-142	-140	-137	-139	-132	-133	-133	-133	-132	-131	-130	-129	-124	-125	-122	-122
Additional Paid-In Capital	0.4%	233	232	233	232	230	229	228	227	226	226	225	226	235	232	231	231	230	229	228	227	227
Shares Outstanding	0.1%	43.00	43.00	43.00	43.00	42.00	42.00	41.00	41.00	41.00	41.00	41.00	40.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	219	-	-	-	142	-	-	-	324	-	-	-	116	-	-	-	73.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-67.4%	1,403	4,303	4,361	3,552	1,812	2,679	649	-190	-1,986	117	-660	768	1,037	2,490	1,597	2,373	2,871	2,220	3,158	657	2,010
Share Based Compensation	-24.2%	1,048	1,382	1,363	1,102	1,153	1,010	1,139	1,239	1,023	1,033	1,004	1,164	968	1,006	1,079	769	793	841	987	615	591
Cashflow From Investing	78.8%	-225	-1,061	-401	-625	288	-235	-442	-442	-471	-358	-480	-206	-301	-314	-564	-283	-241	-456	-361	740	-152
Cashflow From Financing	74.4%	-1,055	-4,116	-2,750	-2,375	-2,893	-2,730	377	-578	94.00	2,594	487	-192	-3,141	3,357	-953	-5,300	-5,071	-429	-658	-1,533	-5,004

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HBIO Income Statement

2024-03-31

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 24,512	$ 29,975
Cost of revenues	9,740	11,629
Gross profit	14,772	18,346
Sales and marketing expenses	5,904	5,978
General and administrative expenses	5,963	6,334
Research and development expenses	2,885	2,897
Amortization of intangible assets	1,333	1,388
Other operating expenses	(966)	0
Total operating expenses	17,051	16,597
Operating (loss) income	(2,279)	1,749
Other (expense) income:
Interest expense	(751)	(974)
Loss on equity securities - Note 6	(1,312)	0
Other (expense) income, net	(142)	432
Total other (expense) income	(2,205)	(542)
(Loss) income before income taxes	(4,484)	1,207
Income tax expense	210	585
Net (loss) income	$ (4,694)	$ 622
(Loss) income per share:
Basic (loss) income per share (in dollars per share)	$ (0.11)	$ 0.01
Diluted (loss) income per share (in dollars per share)	$ (0.11)	$ 0.01
Weighted-average common shares:
Weighted average shares outstanding - basic (in shares)	43,402	42,119
Diluted (in shares)	43,402	42,783

HBIO Balance Sheet

2024-03-31

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,255	$ 4,283
Accounts receivable, net	15,309	16,099
Inventories	24,136	24,716
Other current assets	4,448	3,940
Total current assets	48,148	49,038
Property, plant and equipment, net	4,492	3,981
Operating lease right-of-use assets	4,359	4,773
Goodwill	56,699	57,065
Total intangible assets	14,678	16,036
Other long-term assets	4,785	6,473
Total assets	133,161	137,366
Current liabilities:
Current portion of long-term debt	3,720	5,859
Current portion of operating lease liabilities	1,197	1,416
Accounts payable	6,044	5,554
Contract liabilities	4,388	4,508
Other current liabilities	10,328	9,205
Total current liabilities	25,677	26,542
Long-term debt, net	31,890	30,704
Deferred tax liability	772	776
Operating lease liabilities	4,557	4,794
Other long-term liabilities	1,453	1,476
Total liabilities	64,349	64,292
Commitments and contingencies - Note 13
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized: 43,421,251 shares issued and outstanding at March 31, 2024; 43,394,509 shares issued and outstanding at December 31, 2023	434	434
Additional paid-in-capital	233,451	232,435
Accumulated deficit	(150,299)	(145,605)
Accumulated other comprehensive loss	(14,774)	(14,190)
Total stockholders' equity	68,812	73,074
Total liabilities and stockholders' equity	$ 133,161	$ 137,366

About Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. The company was founded in 1901 and is based in Holliston, Massachusetts.

CEO	Mr. James W. Green
WEBSITE	harvardbioscience.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	436

Harvard Bioscience Inc Frequently Asked Questions

What is the ticker symbol for Harvard Bioscience Inc? What does HBIO stand for in stocks?

HBIO is the stock ticker symbol of Harvard Bioscience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Harvard Bioscience Inc (HBIO)?

As of Fri May 17 2024, market cap of Harvard Bioscience Inc is 147.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HBIO stock?

You can check HBIO's fair value in chart for subscribers.

What is the fair value of HBIO stock?

You can check HBIO's fair value in chart for subscribers. The fair value of Harvard Bioscience Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Harvard Bioscience Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Harvard Bioscience Inc a good stock to buy?

The fair value guage provides a quick view whether HBIO is over valued or under valued. Whether Harvard Bioscience Inc is cheap or expensive depends on the assumptions which impact Harvard Bioscience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HBIO.

What is Harvard Bioscience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, HBIO's PE ratio (Price to Earnings) is -16.86 and Price to Sales (PS) ratio is 1.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HBIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Harvard Bioscience Inc's stock?

In the past 10 years, Harvard Bioscience Inc has provided -0.018 (multiply by 100 for percentage) rate of return.